Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies

Journal of Medicinal Chemistry

Volumn 57, Issue 18, 2014, Pages 7600-7612

  Tang, Weibin ^a   Xie, Jianlin ^a   Xu, Song ^a   Lv, Haining ^a   Lin, Mingbao ^a   Yuan, Shaopeng ^a   Bai, Jinye ^a   Hou, Qi ^a   Yu, Shishan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BRUSATOL; CIGARETTE SMOKE; COMPOUND 75; CROTON OIL; DEXAMETHASONE SODIUM PHOSPHATE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1,2,5-OXADIAZOLE 2-OXIDE; OXADIAZOLE DERIVATIVE; QUASSINOID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; EAR EDEMA; FEMALE; IC50; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; MACROPHAGE; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; FEMALE; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; NITRIC OXIDE; OXADIAZOLES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUASSINS; SMOKING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907459129     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5007534     Document Type: Article

References (58)

1. Polonsky, J. Quassinoid bitter principles II. In Fortschritte der Chemie Organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products; Herz, W., Grisebach. H., Kirby, G. W., Tamm. Ch, Eds.; Springer: Vienna, 1985; pp 221-264.
2. Allen, D.; Toth, I.; Wright, C. W.; Kirby, G. C.; Warhurst, D. C.; Phillipson, J. D. In vitro antimalarial and cytotoxic activities of semisynthetic derivatives of brusatol Eur. J. Med. Chem. 1993, 28, 265-269
3. Hall, I. H.; Liou, Y. F.; Okano, M.; Lee, K. H. Antitumor agents XLVI: In vitro effects of esters of brusatol, bisbrusatol, and related compounds on nucleic acid and protein synthesis of P-388 lymphocytic leukemia cells J. Pharm. Sci. 1982, 71, 345-348
4. Murakami, N.; Sugimoto, M.; Kawanishi, M.; Tamura, S.; Kim, H. S.; Begum, K.; Wataya, Y.; Kobayashi, M. New semisynthetic quassinoids with in vivo antimalarial activity J. Med. Chem. 2003, 46, 638-641
5. Tamura, S.; Fukamiya, N.; Mou, X. Y.; Mukainaka, T.; Tokuda, H.; Nishino, H.; Tagahara, K.; Koike, K.; Lee, K. H.; Okano, M. Conversion of quassinoids for enhancement of inhibitory effect against Epstein-Barr virus early antigen activation. Introduction of lipophilic side chain and esterification of diosphenol Chem. Pharm. Bull. 2000, 48, 876-878
6. Elkhateeb, A.; Tosa, Y.; Matsuura, H.; Nabeta, K.; Katakura, K. Antitrypanosomal activities of acetylated bruceines A and C; a structure-activity relationship study J. Nat. Med. 2012, 66, 233-240
7. Hall, I. H.; Lee, K. H.; Imakura, Y.; Okano, M.; Johnson, A. Anti-inflammatory agents III: structure-activity relationships of brusatol and related quassinoids J. Pharm. Sci. 1983, 72, 1282-1284
8. Kerwin, J. F.; Heller, M. The arginine-nitric oxide pathway: a target for new drugs Med. Res. Rev. 1994, 14, 23-74
9. Änggård, E. Nitric oxide: mediator, murderer, and medicine Lancet 1994, 343, 1199-1206
10. Ignarro, L. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview J. Physiol. Pharmacol. 2002, 53, 503-514
11. Radomski, M. W.; Palmer, R. M.; Moncada, S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium Biochem. Biophys. Res. Commun. 1987, 148, 1482-1489
12. Wallace, J. L.; Granger, D. The cellular and molecular basis of gastric mucosal defense FASEB J. 1996, 10, 731-740
13. Konturek, S.; Konturek, P. C. Role of nitric oxide in the digestive system Digestion 1995, 56, 1-13
14. Lanas, A. Role of nitric oxide in the gastrointestinal tract Arthritis Res. Ther. 2008, 10, S4
15. Wallace, J. L. Nitric oxide as a regulator of inflammatory processes Mem. Inst. Oswaldo Cruz 2005, 100, 5-9
16. Katsuyama, K.; Shichiri, M.; Marumo, F.; Hirata, Y. NO inhibits cytokine-induced iNOS expression and NF-κB activation by interfering with phosphorylation and degradation of IκB-α Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1796-1802
17. Schwentker, A.; Vodovotz, Y.; Weller, R.; Billiar, T. R. Nitric oxide and wound repair: role of cytokines? Nitric Oxide 2002, 7, 1-10
18. Cena, C.; Lolli, M. L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; McElroy, S. P.; Megson, I. L.; Fruttero, R.; Gasco, A. Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin J. Med. Chem. 2003, 46, 747-754
19. Velázquez, C.; Praveen Rao, P. N.; Knaus, E. E. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1, 2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies J. Med. Chem. 2005, 48, 4061-4067
20. 2-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl) diazenium-1, 2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies J. Med. Chem. 2008, 51, 1954-1961
21. Lazzarato, L.; Chegaev, K.; Marini, E.; Rolando, B.; Borretto, E.; Guglielmo, S.; Joseph, S.; Di Stilo, A.; Fruttero, R.; Gasco, A. New nitric oxide or hydrogen sulfide releasing aspirins J. Med. Chem. 2011, 54, 5478-5484
22. Cuzzolin, L.; Conforti, A.; Adami, A.; Lussignoli, S.; Menestrina, F.; Del Soldato, P. Benoni, G. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen Pharmacol. Res. 1995, 31, 61-65
23. Cicala, C.; Ianaro, A.; Fiorucci, S.; Calignano, A.; Bucci, M.; Gerli, R.; Santucci, L.; Wallace, J. L.; Cirino, G. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis Br. J. Pharmacol. 2000, 130, 1399-1405
24. Prasad, P. V.; Bolla, M.; Armogida, M. Use of 4-(nitrooxy)-butyl-(S)-2-(6-methoxy-2-naphthyl)-propanoate for treating pain and inflammation, PCT Int. Appl. WO2008132025, 2008.
25. Wallace, J. L.; Byppiani, S.; Bolla, M. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis Trends Pharmacol. Sci. 2009, 30, 112-117
26. Wey, S. J.; Augustyniak, M. E.; Cochran, E. D.; Ellis, J. L.; Fang, X.; Garvey, D. S.; Janero, D. R.; Letts, L. G.; Martino, A. M.; Melim, T. L. Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors J. Med. Chem. 2007, 50, 6367-6382
27. Wallace, J. L.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M.; Cirino, G. A diclofenac derivative without ulcerogenic properties Eur. J. Pharmacol. 1994, 257, 249-255
28. Li, R. W.; Zhang, Y. H.; Ji, H.; Yu, X. L.; Peng, S. X. Synthesis and anti-inflammatory activity of benzenesulfonylfuroxan-coupled diclofenac Acta Pharm. Sin. 2001, 36, 826-830
29. Li, R. W.; Zhang, Y. H.; Ji, H.; Yu, X. L.; Peng, S. X. Synthesis and anti-inflammatory analgesic activities of phenylfuroxan-coupled diclofenac Acta Pharm. Sin. 2002, 37, 27-32
30. Lolli, M. L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Coruzzi, G.; Manarini, S.; Fruttero, R.; Gasco, A. A new class of ibuprofen derivatives with reduced gastrotoxicity J. Med. Chem. 2001, 44, 3463-3468
31. Liu, J. H.; Zhao, N.; Zhang, G. J.; Yu, S. S.; Wu, L. J.; Ma, S. G.; Chen, X. G.; Zhang, T. Q.; Bai, J.; Chen, H.; Fang, Z. F.; Zhao, F.; Tang, W. B. Bioactive quassinoids from the seeds of Brucea javanica J. Nat. Prod. 2012, 75, 683-688
32. Kenney, W. J.; Walsh, J. A.; Davenport, D. A. An acid-catalyzed cleavage of sulfoxides J. Am. Chem. Soc. 1961, 83, 4019-4022
33. Kelley, J. L.; Mclean, E. W.; Williard, K. Synthesis of bis (arylsulfonyl)) furoxans from aryl nitromethyl sulfones J. Heterocycl. Chem. 1977, 14, 1415-1416
34. Lolli, M. L.; Rolando, B.; Tosco, P.; Chaurasia, S.; Stilo, A. D.; Lazzarato, L.; Gorassini, E.; Ferracini, R.; Oliaro-Bosso, S.; Fruttero, R. Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) Bioorg. Med. Chem. 2010, 18, 2428-2438
35. Chen, L.; Zhang, Y. H.; Kong, X. W.; Lan, E.; Huang, Z. J.; Peng, S. X.; Kaufman, D. L.; Tian, J. D. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid J. Med. Chem. 2008, 51, 4834-4838
36. Gasco, A. M.; Fruttero, R.; Sorba, G.; Gasco, A. Unsymmetrically substituted furoxans, XIII. Phenylfuroxancarbaldehydes and related compounds Liebigs Ann. Chem. 1991, 11, 1211-1213
37. Kim, G. Y.; Kim, J.; Lee, S. H.; Kim, H. J.; Hwang, K. J. Synthesis and Fragmentation of Furoxanaldehydes in the Gas Phase for Nanopatterned Alkyne Formation on a Solid Surface Bull. Korean Chem. Soc. 2009, 30, 459-463
38. Nussler, A. K.; Billiar, T. Inflammation, immunoregulation, and inducible nitric oxide synthase J. Leukocyte Biol. 1993, 54, 171-178
39. Vane, J. R.; Mitchell, J. A.; Appleton, I.; Tomlinson, A.; Bishop-Bailey, D.; Croxtall, J.; Willoughby, D. A. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 2046-2050
40. Barnes, P. J. NO or no NO in asthma? Thorax 1996, 51, 218-220
41. Mariotto, S.; Cuzzolin, L.; Adami, A.; Soldato, P.; Suzuki, H.; Benoni, G. Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils Br. J. Pharmacol. 1995, 115, 225-226
42. Anuar, F.; Whiteman, M.; Siau, J. L.; Kwong, S. E.; Bhatia, M.; Moore, P. K. Nitric oxide-releasing flurbiprofen reduces formation of proinflammatory hydrogen sulfide in lipopolysaccharide-treated rat Br. J. Pharmacol. 2006, 147, 966-974
43. Ongini, E.; Bolla, M. Nitric-oxide based nonsteroidal anti-inflammatory agents Drug Discovery Today: Ther. Strategies 2006, 3, 395-400
44. Kojima, H.; Urano, Y.; Kikuchi, K.; Higuchi, T.; Hirata, Y.; Nagano, T. Fluorescent indicators for imaging nitric oxide production Angew. Chem., Int. Ed. 1999, 38, 3209-3212
45. Tao, L. Z.; Li, X. F.; Zhang, L. L.; Tian, J. Y.; Li, X. B.; Sun, X.; Li, X. F.; Jiang, L.; Zhang, X. J.; Chen, J. Z. Protective effect of tetrahydroxystilbene glucoside on 6-OHDA-induced apoptosis in PC12 cells through the ROS-NO pathway PLoS One 2011, 6, e26055
46. Ferioli, R.; Folco, G. C.; Ferretti, C.; Gasco, A. M.; Medana, C.; Fruttero, R.; Civelli, M.; Gasco, A. A new class of furoxan derivatives as NO donors: mechanism of action and biological activity Br. J. Pharmacol. 1995, 114, 816-820
47. Garvey, E. P.; Oplinger, J. A.; Furfine, E. S.; Kiff, R. J.; Laszlo, F.; Whittle, B. J.; Knowles, R. G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo J. Biol. Chem. 1997, 272, 4959-4963
48. Hu, J.; Luo, C. X.; Chu, W. H.; Shan, Y. A.; Qian, Z. M.; Zhu, G.; Yu, Y. B.; Feng, H. 20-Hydroxyecdysone protects against oxidative stress-induced neuronal injury by scavenging free radicals and modulating NF-κB and JNK pathways PLoS One 2012, 7, e50764
49. Meijer, M.; Rijkers, G. T.; van Overveld, F. J. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease Expert Rev. Clin. Immunol. 2013, 9, 1055-1068
50. Perng, D. W.; Huang, H. Y.; Chen, H. M.; Lee, Y. C.; Perng, R. P. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment Chest 2004, 126, 375-381
51. Yoshida, T.; Tuder, R. M. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease Physiol. Rev. 2007, 87, 1047-1082
52. Hao, B. C.; Zhang, Y. H.; Lai, Y. S.; Yuan, S. T.; Zhang, L. Y. Synthesis and antitumor activity of NO-donating retinoids. Chin. J. Med. Chem. 2007, 17, 213 - 216 and 237.
53. Zou, Z. H.; Lan, X. B.; Qian, H.; Huang, W. L.; Li, Y. M. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents Bioorg. Med. Chem. Lett. 2011, 21, 5934-5938
54. Li, D. H.; Wang, L.; Cai, H.; Zhang, Y. H.; Xu, J. Y. Synthesis and biological evaluation of novel furazan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents Molecules 2012, 17, 7556-7568
55. Shi, J. B.; Xu, S.; Wang, Y. P.; Li, J. J.; Yao, Q. Z. Synthesis of new pyrimidine nucleoside derivatives with nitric oxide donors for antiviral activity Chin. Chem. Lett. 2011, 22, 899-902
56. Lee, K. H.; Tani, S.; Imakura, Y. Antimalarial Agents, 4. Synthesis of a brusatol analog and biological activity of brusatol-related compounds J. Nat. Prod. 1987, 50, 847-851
57. Hitotsuyanagi, Y.; Kim, I. H.; Hasuda, T.; Yamauchi, Y.; Takeya, K. A structure-activity relationship study of brusatol, an antitumor quassinoid Tetrahedron 2006, 62, 4262-4271
58. Tanabe, N.; Hoshino, Y.; Marumo, S.; Kiyokawa, H.; Sato, S.; Kinose, D.; Uno, K.; Muro, S.; Hirai, T.; Yodoi, J. Thioredoxin-1 protects against neutrophilic inflammation and emphysema progression in a mouse model of chronic obstructive pulmonary disease exacerbation PLoS One 2013, 8, e79016